Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Zhonghua yi xue za zhi 2014-Apr

[Cancer clearance for "unprovoked" venous thromboembolism cases].

Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
Veza se sprema u međuspremnik
Wei Ye
Yuexin Chen
Ming Li
Chao Jiang
Donglin Li
Changwei Liu

Ključne riječi

Sažetak

OBJECTIVE

To verify the significance of prospective serum cancer markers clearance program for primary Venous thromboembolism(VTE) cases.

METHODS

During 1 July 2010 within 31 Dec 2012, data from two Chinese vascular centers was prospective registry. All the cases diagnosed as primary VTE by first vascular physicians were underwent serum cancer markers clearance. Long term follow up was required to confirm real cancer occurrence and long term survival rate. A total of 167 cases (106 male and 61 female) were enrolled in this study. Mean age was 52 ± 15 years old.

RESULTS

Eighteen cases (10.78%) were finally scanned as malignant. The sensitive of markers: Carcino-embryonic antigen (CEA) 0.67, carbohydrate antigen (CA)199 0.44, CA242 0.33, CA153 0.44, CA125 0.78, CA724 0.17, combined markers 0.94. The specificity of above markers was 0.97,0.98, 0.98, 0.97, 0.93, 0.97 and 0.86. CA 125 showed best sensitive and specificity as a sole marker. The positive likelihood ratio for markers: CEA 24.83 ((95%CI 8.95-68.90), CA199 22.07 (95%CI 6.43-75.78), CA242 16.56 (95%CI 4.53-60.55), CA153 13.24 (95%CI 4.85-36.17), CA125 10.54 (95%CI 5.67-19.58), CA 724 4.97(95%CI 1.29-19.07), combined of markers 6.70 (95%CI 4.44-10.12). The negative likelihood ratio for markers: CEA 0.34 ((95%CI 0.18-0.66), CA199 0.57 (95%CI 0.37-0.86), CA242 0.68 (95%CI 0.49-0.94), CA153 0.57 (95%CI 0.38-0.87), CA125 0.24 (95%CI 0.10-0.57), CA 724 0.86 (95%CI 0.76-1.06), combined of markers 0.66 (95%CI 0.01-0.44). CEA+CA125 showed better positive and negative likelihood ratio. 6 months, 12 months and 24 months survival rate for malignant (18cases) and non-malignant(149cases) were 61.1%, 50.0%, 31.3% and 99.3%, 98.6%, 98.6% respectively.

CONCLUSIONS

It is reasonable to screening malignant for "unprovoked" VTE cases. Combined multiple serum cancer markers showed best result. CA125 plus CEA showed acceptable result for some limited condition. CA50 was useless for cancer screening.

Pridružite se našoj
facebook stranici

Najkompletnija baza ljekovitog bilja potpomognuta znanošću

  • Radi na 55 jezika
  • Biljni lijekovi potpomognuti znanošću
  • Prepoznavanje bilja slikom
  • Interaktivna GPS karta - označite bilje na mjestu (uskoro)
  • Pročitajte znanstvene publikacije povezane s vašom pretragom
  • Pretražite ljekovito bilje po učincima
  • Organizirajte svoje interese i budite u toku s istraživanjem vijesti, kliničkim ispitivanjima i patentima

Upišite simptom ili bolest i pročitajte o biljkama koje bi mogle pomoći, unesite travu i pogledajte bolesti i simptome protiv kojih se koristi.
* Svi podaci temelje se na objavljenim znanstvenim istraživanjima

Google Play badgeApp Store badge